Trial · NCT06079788
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
NCT06079788, Phase 3, Recruiting, Mao Jianhua
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial. Trials, record NCT06079788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06079788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
- NCT number
- NCT06079788
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Mao Jianhua
- Conditions
- Nephrotic Syndrome in Children
- Interventions
- Adrenocorticotrophic Hormone, Steroid
- First posted
- 2023-10-12
- Last updated
- 2023-10-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence-free survival time(day) within 48 weeks | Within 48 weeks after randomization | Recurrence-free survival time(day) within 48 weeks |
| Secondary | Number of relapses during 48 weeks follow up | Within 48 weeks after randomization | Number of nephrotic syndrome relapses per patient year during the 48 weeks after randomization |
| Secondary | The first time to relapse | Within 48 weeks after randomization | The first time to relapse after patients taking part in this study |
| Secondary | Cumulative prednisone dosage (milligrams per kilogram per year) | Within 48 weeks after randomization | The total dosage of prednisones from the beginning to the end of the trial |
| Secondary | Change in renal function of the patients | Within 48 weeks after randomization | The change for renal function was judged by the changes of serum creatinine and estimated glomerular filtration rate in each follow-up during the study |
| Secondary | Change in anthropometry and growth velocity during 48 weeks after randomization | Within 48 weeks after randomization | Changes in standard deviation scores for weight, height and body mass index during 48 weeks after randomization |
| Secondary | Change in serum cholesterol, hemoglobin and blood albumin of the patients | Within 48 weeks after randomization | The changes of serum cholesterol, hemoglobin and blood albumin in each follow-up during the study |
| Secondary | Incidence of infection | Within 48 weeks after randomization | The incidence of infection during the study |
| Secondary | Adverse event | Within 48 weeks after randomization | The number of harmful reactions and the types of adverse events during the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06079788
GET https://conductscience.org/api/trials/v1/NCT06079788/registered